Warning: Last items in stock!
Hepcdac（Daklinza）Daclatasvir 60mg, is a hepatitis C virus (HCV) NS5A inhibitor indicated for use with sofosbuvir, with or without ribavirin, for the treatment of chronic HCV genotype 1 or 3 infection.
Limitations of Use: Sustained virologic response (SVR12) rates are reduced in genotype 3 patients with cirrhosis receiving Daclatasvir 60mg in combination with sofosbuvir for 12 weeks.
Hepcdac’s brand name is Daklinza by Bristol-Myers Squibb. Hepcdac is a generic oncologic prescription medicine from Cipla, which is one of the biggest pharmaceutical company in India.
|Warnings||Don't take the drug without consulting a qualified doctor or physician|
|Suggested use||Follow the doctor's advice|
|Delivery & Returns||10-20 days|